Literature DB >> 33275531

Cardiac α1A-adrenergic receptors: emerging protective roles in cardiovascular diseases.

Jiandong Zhang1, Paul C Simpson2, Brian C Jensen1.   

Abstract

α1-Adrenergic receptors (ARs) are catecholamine-activated G protein-coupled receptors (GPCRs) that are expressed in mouse and human myocardium and vasculature, and play essential roles in the regulation of cardiovascular physiology. Though α1-ARs are less abundant in the heart than β1-ARs, activation of cardiac α1-ARs results in important biologic processes such as hypertrophy, positive inotropy, ischemic preconditioning, and protection from cell death. Data from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) indicate that nonselectively blocking α1-ARs is associated with a twofold increase in adverse cardiac events, including heart failure and angina, suggesting that α1-AR activation might also be cardioprotective in humans. Mounting evidence implicates the α1A-AR subtype in these adaptive effects, including prevention and reversal of heart failure in animal models by α1A agonists. In this review, we summarize recent advances in our understanding of cardiac α1A-ARs.

Entities:  

Keywords:  cardiovascular disease; catecholamines; heart failure; sympathetic nervous system; α1-adrenergic receptor

Mesh:

Substances:

Year:  2020        PMID: 33275531      PMCID: PMC8082792          DOI: 10.1152/ajpheart.00621.2020

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  95 in total

1.  alpha 1-Adrenergic receptors in guinea pig myocardium: identification by binding of a new radioligand, (3H)-prazosin.

Authors:  J S Karliner; P Barnes; C A Hamilton; C T Dollery
Journal:  Biochem Biophys Res Commun       Date:  1979-09-12       Impact factor: 3.575

2.  Successful treatment of hypotension associated with stunned myocardium with oral midodrine therapy.

Authors:  Sanjiv Sharma; Brijesh Bhambi
Journal:  J Cardiovasc Pharmacol Ther       Date:  2005-03       Impact factor: 2.457

3.  Transgenic alpha1A-adrenergic activation limits post-infarct ventricular remodeling and dysfunction and improves survival.

Authors:  Xiao-Jun Du; Xiao-Ming Gao; Helen Kiriazis; Xiao-Lei Moore; Ziqiu Ming; Yidan Su; Angela M Finch; Ross A Hannan; Anthony M Dart; Robert M Graham
Journal:  Cardiovasc Res       Date:  2006-06-16       Impact factor: 10.787

4.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

Authors: 
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

5.  Differential cardiovascular regulatory activities of the alpha 1B- and alpha 1D-adrenoceptor subtypes.

Authors:  Dan Chalothorn; Dan F McCune; Stephanie E Edelmann; Kimimasa Tobita; Bradley B Keller; Robert D Lasley; Dianne M Perez; Akito Tanoue; Gozoh Tsujimoto; Ginell R Post; Michael T Piascik
Journal:  J Pharmacol Exp Ther       Date:  2003-03-20       Impact factor: 4.030

6.  Different internalization properties of the alpha1a- and alpha1b-adrenergic receptor subtypes: the potential role of receptor interaction with beta-arrestins and AP50.

Authors:  Laura Stanasila; Liliane Abuin; Julien Dey; Susanna Cotecchia
Journal:  Mol Pharmacol       Date:  2008-06-03       Impact factor: 4.436

7.  Norepinephrine in neonatal rat ventricular myocytes: association with the cell nucleus and binding to nuclear alpha 1- and beta-adrenergic receptors.

Authors:  N T Buu; R Hui; P Falardeau
Journal:  J Mol Cell Cardiol       Date:  1993-09       Impact factor: 5.000

8.  Carvedilol induces biased β1 adrenergic receptor-nitric oxide synthase 3-cyclic guanylyl monophosphate signalling to promote cardiac contractility.

Authors:  Qingtong Wang; Ying Wang; Toni M West; Yongming Liu; Gopireddy R Reddy; Federica Barbagallo; Bing Xu; Qian Shi; Bingqing Deng; Wei Wei; Yang K Xiang
Journal:  Cardiovasc Res       Date:  2021-08-29       Impact factor: 10.787

9.  Nuclear localization of a1A-adrenergic receptors is required for signaling in cardiac myocytes: an “inside-out” a1-AR signaling pathway.

Authors:  Steven C Wu; Erika F Dahl; Casey D Wright; Andrew L Cypher; Chastity L Healy; Timothy D O'Connell
Journal:  J Am Heart Assoc       Date:  2014       Impact factor: 5.501

10.  Gαi is required for carvedilol-induced β1 adrenergic receptor β-arrestin biased signaling.

Authors:  Jialu Wang; Kenji Hanada; Dean P Staus; Michael A Makara; Giri Raj Dahal; Qiang Chen; Andrea Ahles; Stefan Engelhardt; Howard A Rockman
Journal:  Nat Commun       Date:  2017-11-22       Impact factor: 14.919

View more
  5 in total

1.  Midodrine to optimize heart failure therapy in patients with concurrent hypotension.

Authors:  Paul Shiu; Gurinder S Grewal; Teri M Kozik
Journal:  SAGE Open Med Case Rep       Date:  2022-05-18

2.  Chinese Classical Music Lowers Blood Pressure and Improves Left Ventricular Hypertrophy in Spontaneously Hypertensive Rats.

Authors:  Jingyuan Li; Zhi Yang; Chunmei Zhang; Yang Hu; Hongxuan Li; Meng Zhang; Peili Bu; Shuangxi Wang; Cheng Zhang; Wenjing Li
Journal:  Front Pharmacol       Date:  2022-05-02       Impact factor: 5.988

Review 3.  Modification of Ischemia/Reperfusion-Induced Alterations in Subcellular Organelles by Ischemic Preconditioning.

Authors:  Paramjit S Tappia; Anureet K Shah; Bram Ramjiawan; Naranjan S Dhalla
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

4.  Associations between β-Blocker Therapy at Discharge and Long-Term Follow-Up Outcomes in Patients with Unstable Angina Pectoris.

Authors:  Lei Liu; Xiaosong Ding; Hui Chen; Weiping Li; Hongwei Li
Journal:  Cardiol Res Pract       Date:  2022-09-29       Impact factor: 1.990

5.  Programming With Varying Dietary Fat Content Alters Cardiac Insulin Receptor, Glut4 and FoxO1 Immunoreactivity in Neonatal Rats, Whereas High Fat Programming Alters Cebpa Gene Expression in Neonatal Female Rats.

Authors:  Annelene Govindsamy; Samira Ghoor; Marlon E Cerf
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-05       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.